Loading
Grace Therapeutics, Inc. Stock: price and insider trades · United States
2 insiders bought €539k of shares over the last 90 days, the latest by Opaleye Management Inc., filed 21 Oct 2026.
Grace Therapeutics, Inc.: what insiders have been doing
Grace Therapeutics, Inc. belongs to the Health Care sector. Filings by its managers are published through SEC (Form 4). In the past year (22 October 2025 to 22 October 2026), 29 filings came from 10 insiders.
No insider sold shares on the market over the period. Instead, the filings list 19 purchases totalling €822k, made by 3 insiders. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. At €184k, the purchase published on 10 September 2026 by Kohli Prashant is the largest of the period (0.52% of market cap). Among those who bought: 1 major shareholder, 1 senior executive and 1 chief executive.
Across the 3,171 companies tracked on its exchange, the median is 24 filings; at 29 filings, this issuer sits above that mark. Since 2023, the database holds 21 purchases and no sales by insiders of the company.
The data flag 10 purchases as part of a group of insiders buying within 30 days of each other. A cluster is several different insiders buying the same stock within a short window, a pattern studied more closely than a single purchase. The most recent open-market purchase was published on 21 October 2026, 3 days ago. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 4 days. The legal deadline for a Form 4 is two business days after the transaction.
Other companies in the same sector with recent insider buying flagged by our signals: UCB. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Insider Decl.
32
Thresholds
n/a
Buy Volume
€2M
21 ops. · all time
Sell Volume
n/a
n/a
Who traded when
BuySaleOpaleye Management Inc.16 buys
Prashant Kohli3 buys
Since the insiders bought
- -10.8%Entry US$2.22 · Close 20 Oct 2026 US$1.98
- -10.8%Entry US$2.22 · Close 20 Oct 2026 US$1.98
- +5.8%Entry US$2.95 · Close at T+365 US$3.12
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
This score ranks the purchase within its own market. A position size is suggested only on the venues of the backtested strategy universe; elsewhere, signals stay on watch. Not investment advice.
Financial data
as of FY 2024FY ended March 2024 · cache
US$1.97
Analyst consensus
2 analysts1.00/5
US$3.96Target US$5.95(+202%)US$7.95
Income statement
EBITDA-US$11.1M
Net income-US$7.8M0.0% margin
Valuation
PER (forward)-3.1x
P/Book0.7x
Beta0.33
Balance sheet & cash
Market capUS$41.4M
Free Cash Flow-US$8.9M
Profitability & ownership
ROE-36.2%
ROA-10.8%
% insiders18.7%
% institutions31.6%
Last declaration on 21 October 2026
Declarations32 total
4,256 shares@ US$1.880.020% mcap2.0% of flowCommon Stock, par value $0.0001 per shareSEC:0001493152-26-047949:0
Canonical exit: 17 Jan 2027 (T+90)
11,233 shares@ US$1.93490.055% mcap5.6% of flowCommon Stock, par value $0.0001 per shareSEC:0001493152-26-047473:0
Canonical exit: 12 Jan 2027 (T+90)
23,485 shares@ US$1.94530.11% mcap11.7% of flowCommon Stock, par value $0.0001 per shareSEC:0001493152-26-047473:1
Canonical exit: 13 Jan 2027 (T+90)
36,347 shares@ US$1.89170.17% mcap17.6% of flowCommon Stock, par value $0.0001 per shareSEC:0001493152-26-047473:2
Canonical exit: 14 Jan 2027 (T+90)
2,077 shares@ US$2.01750.0099% mcap1.7% of flowCommon Stock, par value $0.0001 per shareSEC:0001493152-26-046899:0
Canonical exit: 6 Jan 2027 (T+90)
5,340 shares@ US$2.04460.026% mcap4.3% of flowCommon Stock, par value $0.0001 per shareSEC:0001493152-26-046899:1
Canonical exit: 7 Jan 2027 (T+90)
7,215 shares@ US$2.020.034% mcap5.7% of flowCommon Stock, par value $0.0001 per shareSEC:0001493152-26-046899:2
Canonical exit: 10 Jan 2027 (T+90)
38,796 shares@ US$2.03530.18% mcap34.8% of flowCommon Stock, par value $0.0001 per shareSEC:0001493152-26-045809:0
Canonical exit: 30 Dec 2026 (T+90)
20,000 shares@ US$2.06840.095% mcap18.4% of flowCommon Stock, par value $0.0001 per shareSEC:0001493152-26-045809:1
Canonical exit: 31 Dec 2026 (T+90)
1,694 shares@ US$2.060.0080% mcap1.6% of flowCommon Stock, par value $0.0001 per shareSEC:0001493152-26-045809:2
Canonical exit: 3 Jan 2027 (T+90)
7,849 shares@ US$2.090.037% mcap16.0% of flowCommon Stock, par value $0.0001 per shareSEC:0001493152-26-045358:0
Canonical exit: 28 Dec 2026 (T+90)
9,771 shares@ US$2.100.050% mcap5.1% of flowCommon Stock, par value $0.0001 per shareSEC:0001493152-26-043996:0
Canonical exit: 20 Dec 2026 (T+90)
5,318 shares@ US$2.100.028% mcap2.8% of flowCommon Stock, par value $0.0001 per shareSEC:0001493152-26-043996:1
Canonical exit: 22 Dec 2026 (T+90)
12,200 sharesOptionsTSXSEDI:4780035
12,200 sharesOptionsTSXSEDI:4780034
12,200 sharesOptionsTSXSEDI:4780033
12,200 sharesOptionsTSXSEDI:4780030
100,000 shares@ CA$2.140.38% mcap47.0% of flowCommon Shares (Actions de catégorie A)TSXSEDI:4776267
Canonical exit: 8 Dec 2026 (T+90)
100,000 shares@ CA$2.410.43% mcap53.0% of flowCommon Shares (Actions de catégorie A)TSXSEDI:4776190
Canonical exit: 8 Dec 2026 (T+90)
100,000 shares@ US$2.140.52% mcap100.0% of flowCommon StockSEC:0001140361-26-036125:0
Canonical exit: 8 Dec 2026 (T+90)
9,393 shares@ US$2.09720.048% mcap4.8% of flowCommon Stock, par value $0.0001 per shareSEC:0001493152-26-042152:0
Canonical exit: 7 Dec 2026 (T+90)
5,836 shares@ US$2.08990.030% mcap3.0% of flowCommon Stock, par value $0.0001 per shareSEC:0001493152-26-042152:1
Canonical exit: 8 Dec 2026 (T+90)
267,160 sharesOptionsTSXSEDI:4771565
35,760 sharesOptionsTSXSEDI:4771558
54,690 sharesOptionsTSXSEDI:4771550
25 of 32 declarations
About Grace Therapeutics, Inc.
Grace Therapeutics, Inc. is a company focused on developing innovative therapies. It is listed on the XNAS market.
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
